Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of Cogent Biosciences (NasdaqGS:COGT) with a ...

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...

Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...

Investing.com -- Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.

Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for ...

Wall Street ended sharply higher on Monday, led by big gains in Nvidia, Palantir and other heavyweight AI-related companies ...

Markets are coming back strong. All thanks to the news that the government shutdown may soon be over, which would remove a ...

Companies don’t generally cut prices out of generosity.

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Operator: Ladies and gentlemen, thank you for joining us today. And third quarter 2025 results conference call. At this time, ...

Leerink lowered the firm’s price target on uniQure (QURE) to $60 from $68 and keeps an Outperform rating on the shares following quarterly results ...

Nvidia (NVDA.O), the world's most valuable company, rose 5.8%. AI data analytics firm Palantir (PLTR.O) jumped 8.8% and Tesla (TSLA.O) climbed 3.7%.